AstraZeneca Pharma India has announced the appointment of Gagan Singh Bedi as managing director with effect from July 1,2017. This is pursuant to Sanjay Murdeshwar, the erstwhile managing director moving on to take a global role within the AstraZeneca Group based in Gaithersburg, Maryland, USA. Murdeshwar resigned as managing director of the company, ipso facto, as a director of the company on June 30, 2017. The board accepted his resignation.
In addition, the board co-opted Gagan Singh Bedi as additional director on the board, who took over as the managing director of the company. Bedi joined AstraZeneca Pharma India in February 2006. He held initial roles as business director and later as director, strategic planning. Thereafter, he was promoted to the role of vice president, sales & marketing: cardiovascular and diabetes.
In 2012, he was appointed as country president for AstraZeneca Philippines. Post a successful career stint in this role, he moved to the UK as global head of established brands and global medical lead, gastrointestinal and cardiovascular.
Prior to AstraZeneca, he worked with Baxter India and Eli Lily. Beidi is a graduate in economics from the Delhi University.
“We are pleased at the appointment of Gagan Singh Bedi as the managing director, AstraZeneca Pharma India Limited. Gagan’s expertise and entrepreneurial leadership will be pivotal to the growth of the India business as we continue to strengthen our focus on addressing unmet needs in three main therapy areas - cardiovascular metabolic diseases, respiratory and oncology. We would also like to thank and congratulate Sanjay Murdeshwar for his outstanding contribution to the company and his next assignment in a global role within AstraZeneca,” said Smita Saha, VP – HR & HR regional lead, AstraZeneca India.